Acute pancreatitis following orlistat therapy: Report of two cases

Journal of the Pancreas

Volumn 11, Issue 1, 2010, Pages 61-63

  Ahmad, Faheem Asem ^a   Mahmud, Sajid ^a  

^a HAIRMYRES HOSPITAL   (United Kingdom)

Author keywords

Drug toxicity; Orlistat; Pancreatitis, acute necrotizing

Indexed keywords

AMYLASE; FLUOXETINE; INFUSION FLUID; LEVOMEPROMAZINE; OMEPRAZOLE; PANCREAS ENZYME; TETRAHYDROLIPSTATIN; THIAMINE; VENLAFAXINE; VITAMIN B GROUP;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; ANALGESIA; ANAMNESIS; ARTICLE; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DEPRESSION; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG SAFETY; FEMALE; FLUID THERAPY; HIATUS HERNIA; HUMAN; LONG TERM CARE; NAUSEA AND VOMITING; OBESITY;

ACUTE DISEASE; AGED; ANTI-OBESITY AGENTS; FEMALE; HUMANS; LACTONES; MIDDLE AGED; OBESITY; PANCREATITIS;

EID: 74749106038     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354:2142-50. [PMID 16707751]
2. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf 1996; 14:406-23. [PMID 8828018]
3. Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report. Nutr J 2006; 5:19. [PMID 16938137]
4. Working Party of the British Society of Gastroenterology. Association of Surgeons of Great Britain and Ireland; Pancreatic Society of Great Britain and Ireland; Association of Upper GI Surgeons of Great Britain and Ireland UK guidelines for the management of acute pancreatitis. Gut 2005; 54 S3:1-9. [PMID 15831893]
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45. [PMID 7249508]
6. Proietto J, Fam BC, Ainslie DA, Thorburn AW. Novel antiobesity drugs. Expert Opin Investig Drugs 2000; 9:1317-26. [PMID 11060745]
7. National Institute for Clinical Excellence. Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. Clinical Guideline 43. London: NICE, 2006.
8. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21:S12-23. [PMID 9225172]
9. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1987; 35:1103-8. [PMID 8626884]
10. Caner M, Dogruman H, Taskin E, Kandil A, Demirci C. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 2005; 48:217-22. [PMID 16548424]
11. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31:53-65. [PMID 18095746]
12. Kim DH, Lee EH, Hwang JC, Jeung JH, Kim do H, Cheong JY et al. A case of acute cholestatic hepatitis associated with orlistat [in Korean]. Taehan Kan Hakhoe Chi 2002; 8: 317-20. [PMID 12499790]
13. Montero JL, Muntane J, Fraga E, Delgado M, Costán G, Serrano M et al. Orlistat associated subacute hepatic failure. J Hepatol 2001; 34:173. [PMID 11211898]
14. Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005; 17:1437-8. [PMID 16292105]
15. Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat? Med Sci Law 2002; 42:309-12. [PMID 12487515]
16. Torgerson J, Hauptman J, Boldrin M, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-61. [PMID 14693982]
17. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235-42. [PMID 9918478]
18. British National Formulary. 58 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
19. GlaxoSmithKline. GlaxoSmithKline receives European Commission approval to market alli (orlistat 60mg).[online]
20. US Food and Drug Administration. FDA approves orlistat for over-the-counter use [online].